Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin-Nan Cheng

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
The Journal of Pathology|July 12, 2017
Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virusWen-Chun Liu, I-Chin Wu, Yen-Chien Lee, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
The Journal of Pathology|July 12, 2017
Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virusWen-Chun Liu, I-Chin Wu, Yen-Chien Lee, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Pageof 14